"N60" might not be the first thing that comes to mind when people think of Alzheimer's disease, but thanks to researchers from the United States, South Korea and France, this might change. That's because these researchers have found that the N60 section of a protein called "RanBP9" might be the key that unlocks an entirely new class of Alzheimer's drugs, and with them, hope. In a research report published online in The FASEB Journal (http://www.fasebj.org), these scientists describe how the N60 fragment of the RanBP9 protein increases the production of the amyloid beta protein, which is present in excessive amounts in the brains of people with Alzheimer's disease.
Most experts believe that if the creation of amyloid beta protein can be halted or slowed, the devastating effects of Alzheimer's disease may also be stopped or slowed too. Knowing which portion of the RanBP9 protein to target is particularly important because it gives researchers a more specific focus for developing new Alzheimer's drugs.
According to David Kang, assistant professor of neurosciences at the University of California, San Diego, and one of the researchers involved in the work, "Our study suggests that targeting RanBP9 expression and/or N60 fragment generation may lead to novel strategies to combat this devastating disease."
To make this discovery, Kang and colleagues examined extracts from brains with Alzheimer's disease and age-matched healthy controls and found that the N60 section of RanBP9 was increased in Alzheimer's brain. When control DNA, full-length RanBP9 DNA, and RanBP9-N60 DNA were individually expressed in cultured cells, they found that cells expressing the full length RanBP9 protein had an increased amount of the amyloid beta protein that was 3-fold over control, and cells expressing the RanBP9 protein and N60 section had an increased amount of the amyloid beta protein that was 5-fold over control.
|Contact: Cody Mooneyhan|
Federation of American Societies for Experimental Biology